---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013308"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T05:53:22.650015+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KALA BIO Q2 net loss $10.4M; cash $59.2M; CHASE trial topline data expected Q2 2024

## Summary
- Net loss of $10.4M ($4.36/share) vs $28.1M ($18.92/share) in Q2 2022; operating loss $9.6M.
- Cash, equivalents and short-term investments $59.2M as of June 30, 2023; CIRM $15M grant extends runway into Q2 2025.
- CHASE Phase 2b trial for KPI-012 in PCED actively enrolling; topline data targeted for Q2 2024.
- No product revenue after sale of commercial portfolio to Alcon in July 2022; SG&A fell to $5.0M from $22.7M.
- Rebranded to KALA BIO from Kala Pharmaceuticals, reflecting focus on biologics for rare ophthalmic diseases.

## SEC filing metadata
- accession: 0001558370-23-013308
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837023013308/0001558370-23-013308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837023013308/kala-20230804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013308
- JSON: https://secwatch.observer/filing/0001558370-23-013308.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.